Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a cancer vaccine prime the body to better fight liver tumors?

NCT ID NCT07726329

Disease control Sponsor: Chang Gung Memorial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial tests whether giving a personalized dendritic cell vaccine before a standard liver-directed therapy (TACE) can improve outcomes for people with advanced liver cancer that has not responded to other treatments. The vaccine is made from the patient's own immune cells and trained to recognize their tumor. The study will measure safety, tumor shrinkage, and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a dendritic cell vaccine followed by transcatheter arterial chemoembolization (TACE)
What this could lead to
If it works, this combination approach could offer a new treatment option for people with advanced liver cancer who have run out of standard options.
What could go wrong
This is a mid-stage trial with 100 participants, so results are not yet proven. The treatment involves two complex procedures and may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2019

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * advanced HCC patients, no response to standard treatment; WBC : 3000-12000/ul; platelet: \>80000/ul; anticipated survival \> 3 months, measurable tumors. Exclusion Criteria: * HIV; BCLC stage; acute infection; sepsis; other advanced malignancy; acute liver failure;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma liver and intrahepatic bile duct neoplasm Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver neoplasms

Contacts and locations

Locations

  • Chang-Gung Memorial Hospital

    Taoyuan, 33357, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.